Skip to main content

Advertisement

Table 1 Main characteristics of the studies and patients enrolled in this comprehensive analysis

From: Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis

Study Study design Study period Regimen N SVR12 (%) Mean ± SD (Age, year) Male (%) Cirrhosis (Yes|No) TN|TE GT1|GT4
Rios (2018) observational study 2014.12–2016.8 OPr ± D ± R 440 420 (95.5) 51.0 ± 1.2 NA 101|339 NA 299|125
Pineda (2018) cohort 2015.3–2017.1 OPrD±R 182 172 (94.5) 51.0 ± 1.2 151 (82.9) 69|113 101|81 GT1
Massimo (2017) cohort NA OPrD±R 210 203 (96.7) 53.0 ± 7.8 157 (74.8) 23|187 96|114 GT1
Rockstroh (2017) clinical trial 2015.7–2015.12 OPrD±R 228 221 (96.9) 50.0 ± 7.2 171 (75.0) 23|205 151|76 200|28
Bhattacharya (2017) observational cohort 2016.4 OPrD±R 89 79 (88.8) 61.4 ± 6.1 89 (100) 14|75 79|10 GT1
Sulkowski (2015) clinical trial 2013.9–2014.8 OPrD+R 63 58 (92.1) 50.9 ± 7.2 58 (92.0) NA 42|21 GT1
Montes (2017) observational study 2015.4–2015.12 OPr ± D ± R 88 87 (98.9) 51.4 ± 1.0 67 (76.1) NA NA NA
Wyles (2017) clinical trial 2014.12–2015.7 OPrD+R 22 22 (100.0) NA 17 (77.3) 3|19 19|3 GT1
Steiner (2017) cohort 2016.4 OPr ± D 14 14 (100.0) 41.9 ± 3.2 9 (66.7) NA NA 11|3
Milazzo (2017) observational study 2014.12–2015.12 OPrD±R 22 20 (90.9) 51.5 ± 3.1 NA NA NA GT1
  1. *OPrD ombitasvir/ paritaprevir/ritonavir plus dasabuvir, OPr ombitasvir/ paritaprevir/ritonavir; D dasabuvir, R RBV, GT genotype, TN treatment-naive, TE treatment-experienced, NA not applicable